|
Partnering Events:
|
 |
|
|
Systemic Delivery of Targeted, siRNA-Containing Nanoparticles for the Treatment of Solid Tumors: Concept to Clinic
J.D. Heidel, J.Y-C. Liu, R.K. Zeidan, Y. Liang, S. Rele, M.E. Davis
Calando Pharmaceuticals, US
Keywords:
siRNA, deliery, RRM2, nanoparticle, transferrin
Abstract:
Calando Pharmaceuticals is developing siRNA-containing nanoparticle formulations, and its leading formulation that will enter the clinic in 2008 contains the human transferrin protein as a targeting ligand and siRNA targeting the M2 subunit of ribonucleotide reductase (RRM2). Critical parameters in the formulation and function of this therapeutic system will be highlighted using data from pre-clinical investigations. Anti-tumor efficacy is enhanced when the targeted version of the nanoparticles are employed, and results from numerous safety and efficacy studies will be discussed.
Nanotech 2008 Conference Program Abstract
|
